Global Synchronized Oncology Development: Integrating High-Impact Regions to Accelerate Trial Readiness

17

June

  • 3PM London / 10AM New York
  • Free
  • Why attend?
  • Speakers
  • Contact Us

Why attend?

This 60-minute webinar will focus on how sponsors can operationalize globally synchronized oncology development to accelerate timelines while maintaining consistency across regions. The session will explore how to align regulatory, clinical, and operational strategies across major markets, with a practical lens on integrating high-impact but often underutilized regions such as China into global programs.

Key topics will include:

  • Translating evolving regulatory acceleration pathways into globally executable plans
  • Aligning protocol design, site readiness, and ethics submissions across regions to avoid delays
  • Maintaining global protocol consistency while accommodating regional requirements
  • Building risk management and initiation strategies that support parallel—not sequential—development
  • Leveraging regional opportunities (including China’s accelerated timelines) without disrupting global milestones

 

The session will emphasize execution planning that preserves global timelines while expanding patient access and data diversity across regions—a growing priority for oncology sponsors operating in increasingly complex, multi-regional environments.

Speakers

Select a speaker to learn more

Back
Adam Callahan, MS, MBA
VP Global Therapeutic Area Head, Oncology & Hematology, Caidya

Adam Callahan is VP Global Therapeutic Area Head, Oncology & Hematology at Caidya. Adam brings nearly 30 years of experience and a strong record of building high-performing, global teams that drive clinical programs for regulatory approval and commercialization of therapies. Adam leads a team of medical, scientific, and clinical development experts who engage early and often to help refine sponsor strategies, improve targeting, and accelerate delivery.

Adam’s teams also bring an adeptness in molecule-to-market strategies and operational excellence. Adam’s operational acumen ensures Caidya’s ability to provide development strategies while delivering exceptional experiences for our clients.

Next speaker
Back
Ed Dow
M.D

Dr. Dow is a board-certified Medical Oncologist with over 30 years of experience in clinical research and medicine, including classic chemotherapy agents, and modern products like molecular-targeted, checkpoint inhibitors and vaccines. Skilled in solid tumor studies both from a safety and response assessment perspective, Dow has led many FIH and early phase study in a wide variety of relapsed/refractory solid tumors providing not only medical monitoring but a strategic medical disease-oriented approach.

Next speaker
Back
Susan Kong
VP Regulatory & Strategic Development

With 18 years of experience in multinational pharmaceutical companies and CROs, including Roche, GlaxoSmithKline, Sanofi, and Kandiya, she specializes in regulatory affairs and registration strategy for innovative drugs and biologics in China. As Head of the Registration Affairs and Strategy Department, Susan Kong leads end-to-end product registration planning from IND to NDA, overseeing lifecycle regulatory pathways. Her expertise spans oncology, immunology, anti-infectives, CNS, and respiratory diseases, with deep knowledge of Chinese and U.S. regulatory requirements and extensive experience in global drug registration processes.

Next speaker

Enquiry